Naveglitazar

Drug Profile

Naveglitazar

Alternative Names: LY 519818; LY 818; LY 9818

Latest Information Update: 11 Apr 2011

Price : $50

At a glance

  • Originator Ligand Pharmaceuticals
  • Class Antihyperglycaemics; Phenylpropionates; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 12 Jul 2004 Eli Lilly will review and revise their plans for the phase III clinical trials of naveglitazar accordingly to the FDA's new guidelines
  • 16 Jun 2004 Data presented at the 64th Scientific Sessions of the American Diabetes Association (ADA-2004) have been added to the Diabetes pharmacodynamics section
  • 03 Mar 2004 Eli Lilly is advancing LY 519818 into phase III studies for Type-2 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top